Romatoid artritte LRG1 düzeyinin hastalık aktivite indeksleriyle ilişkisi
Yükleniyor...
Dosyalar
Tarih
2022
Yazarlar
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Hatay Mustafa Kemal Üniversitesi
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
Amaç: Romatoid artrit (RA)'de yeni bir biyobelirteç olan Leucine-rich alpha-2-glycoprotein 1 (LRG-1) molekülünün hastalık aktivite indeksleri ile olan ilişkisini belirlemektir. Gereç ve Yöntem: Çalışmanın örneklemi, Hatay Mustafa Kemal Üniversitesi Hastanesi Romatoloji polikliniğinde tanı alan ve takip edilen 35 remisyon elde edilmiş, 35 düşük hastalık aktivitesi gösteren, 35 orta hastalık aktivitesi gösteren ve 35 yüksek hastalık aktivitesi gösteren olmak üzere 140 romatoid artrit hastasından ve 35 sağlıklı kontrolden oluşmaktadır. Çalışmaya alınan tüm hasta ve sağlıklı bireylerin sosyodemografik bilgileri kaydedildi. Çalışmaya alınan hastaların hassas/şiş eklemleri belirlenmiş, Disease Activity Score 28 (DAS28), Clinical Disease Activity Index (CDAI), Simplified Disease Activity Index (SDAI) ve Routine Assessment of Patient Indeks Data 3 (RAPİD3) hesaplandı. Çalışmaya alınan tüm hasta ve sağlıklı bireylerin serumunda LRG1, TGFβ, IL-6 ve TNF-α düzeyleri ölçüldü. Bulgular: Çalışmamızda RA hasta grubunun LRG1, TNF‐α, IL-6 ve TGF- β1 düzeyleri kontrol grubuna kıyasla daha yüksek olduğu tespit edildi. Hastaların LRG1 ortanca değeri 226,03 (100,15-805,95), kontrol grubunda yer alan bireylerin LRG1 ortanca değeri 117,19 (74,73-156,61) idi (p<0,001). Hastaların TGF-β1 ortanca değeri 257,07 (185,05-990,80), kontrol grubunda yer alan bireylerin TGF-β1 ortanca değeri 214,60 (163,78-359,07) idi (p<0,001). Hastaların TNF-α ortanca değeri 134,26 (90,33-713,80), kontrol grubunda yer alan bireylerin TNF-α ortanca değeri 118,18 (89,90-146,10) idi (p<0,001). Hastaların IL-6 ortanca değeri 134,26 (90,33-713,80), kontrol grubunda yer alan bireylerin IL-6 ortanca değeri 118,18 (89,90-146,10) idi (p=0,002). LRG1 düzeylerinin, yüksek hastalık aktivitesi olan grupta diğer gruplara kıyasla anlamlı derecede yüksek olduğu tespit edildi (p<0,001). LRG1 ile TNF-α ve IL-6 arasında pozitif yönde orta düzeyde bir ilişki tespit edildi. LRG1 düzeyleri ile DAS28, CDAI, SDAI ve RAPID3 skorları arasında pozitif yönde güçlü bir ilişki tespit edildi. TNF-α ve IL-6 düzeyleri ile DAS28, CDAI, SDAI ve RAPID3 skorları arasında ise pozitif yönde orta düzeyde bir ilişki tespit edildi. Yapılan ROC analizi neticesinde RA hastalığının takibinde serum LRG1 düzeyinin başarılı bir performansa sahip olduğu tespit edildi (p<0,001). Sonuç: LRG1'in RA'daki sistemik inflamasyon yükünü yansıttığını ve inflamatuar süreçte rol oynayabileceğini düşündürmektedir. LRG1, RA'lı hastalarda yararlı bir hastalık aktivite belirteci olabilir.
Aims: Aim of this study is to determine the relation between Leucine-rich alpha-2-glycoprotein 1 (LRG1) a new biomarker in Romatoid Artrit (RA) and disease activity index. Materials and Methods: The sample of the study consisted of 140 rheumatoid arthritis patients followed in Hatay Mustafa Kemal University Hospital Rheumatology outpatient clinic, 35 of whom achieved remission, 35 with low disease activity, 35 with moderate disease activity, and 35 with high disease activity, and 35 healthy controls. Socio-demographic data of all patients and healthy individuals included in the study were recorded. Tender/swelling joints of the patients included in the study were determined, Disease Activity Score 28 (DAS28), Clinical Disease Activity Index (CDAI), Simplified Disease Activity Index (SDAI) and Routine Assessment of Patient Index Data 3 (RAPID3) were calculated. LRG1, TGFβ, IL-6 and TNF-α levels were measured in the serum of all patients and healthy individuals included in the study. Results: In our study, LRG1, TNF-α, IL-6, and TGF‐β1 levels of the RA patient group were found to be higher than the control group. The median LRG1 value of the patients was 226.03 (100.15-805.95), and the median LRG1 value of the individuals in the control group was 117.19 (74.73-156.61) (p<0.001). The median TGF-β1 value of the patients was 257.07 (185.05-990.80) and the median TGF-β1 value of the individuals in the control group was 214.60 (163.78-359.07) (p<0.001). The median TNF-α value of the patients was 134.26 (90.33-713.80), and the median TNF-α value of the individuals in the control group was 118.18 (89.90-146.10) (p<0.001). The median IL-6 value of the patients was 134.26 (90.33-713.80), and the median IL-6 value of the individuals in the control group was 118.18 (89.90-146.10) (p=0.002). LRG1 levels were found to be significantly higher in the group with high disease activity compared to the other groups (p<0,001). A moderate positive correlation was detected between LRG1 and TNF-α and IL-6. A strong positive correlation was detected between LRG1 levels and DAS28, CDAI, SDAI and RAPID3 scores. A moderate positive correlation was found between TNF-α and IL-6 levels and DAS28, CDAI, SDAI and RAPID3 scores. As a result of the ROC analysis, it was determined that the serum LRG1 level had a successful performance in the follow-up of RA disease (p<0,001). Conclusion: It suggests that LRG1 reflects the burden of systemic inflammation in RA and may play a role in the inflammatory process. LRG1 may be a useful marker of disease activity in patients with RA. Key words: LRG1, rheumatoid arthritis, disease activity, TGFβ, IL-6, TNF-α
Aims: Aim of this study is to determine the relation between Leucine-rich alpha-2-glycoprotein 1 (LRG1) a new biomarker in Romatoid Artrit (RA) and disease activity index. Materials and Methods: The sample of the study consisted of 140 rheumatoid arthritis patients followed in Hatay Mustafa Kemal University Hospital Rheumatology outpatient clinic, 35 of whom achieved remission, 35 with low disease activity, 35 with moderate disease activity, and 35 with high disease activity, and 35 healthy controls. Socio-demographic data of all patients and healthy individuals included in the study were recorded. Tender/swelling joints of the patients included in the study were determined, Disease Activity Score 28 (DAS28), Clinical Disease Activity Index (CDAI), Simplified Disease Activity Index (SDAI) and Routine Assessment of Patient Index Data 3 (RAPID3) were calculated. LRG1, TGFβ, IL-6 and TNF-α levels were measured in the serum of all patients and healthy individuals included in the study. Results: In our study, LRG1, TNF-α, IL-6, and TGF‐β1 levels of the RA patient group were found to be higher than the control group. The median LRG1 value of the patients was 226.03 (100.15-805.95), and the median LRG1 value of the individuals in the control group was 117.19 (74.73-156.61) (p<0.001). The median TGF-β1 value of the patients was 257.07 (185.05-990.80) and the median TGF-β1 value of the individuals in the control group was 214.60 (163.78-359.07) (p<0.001). The median TNF-α value of the patients was 134.26 (90.33-713.80), and the median TNF-α value of the individuals in the control group was 118.18 (89.90-146.10) (p<0.001). The median IL-6 value of the patients was 134.26 (90.33-713.80), and the median IL-6 value of the individuals in the control group was 118.18 (89.90-146.10) (p=0.002). LRG1 levels were found to be significantly higher in the group with high disease activity compared to the other groups (p<0,001). A moderate positive correlation was detected between LRG1 and TNF-α and IL-6. A strong positive correlation was detected between LRG1 levels and DAS28, CDAI, SDAI and RAPID3 scores. A moderate positive correlation was found between TNF-α and IL-6 levels and DAS28, CDAI, SDAI and RAPID3 scores. As a result of the ROC analysis, it was determined that the serum LRG1 level had a successful performance in the follow-up of RA disease (p<0,001). Conclusion: It suggests that LRG1 reflects the burden of systemic inflammation in RA and may play a role in the inflammatory process. LRG1 may be a useful marker of disease activity in patients with RA. Key words: LRG1, rheumatoid arthritis, disease activity, TGFβ, IL-6, TNF-α
Açıklama
Anahtar Kelimeler
İç Hastalıkları, Internal diseases, LRG1, romatoid artrit, hastalık aktivitesi, TGFβ, IL-6, TNF-α
